This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Checked against the public recordLast updated Aug 24, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Genzyme, a Sanofi Company
- Interventions being studied
- Drug: ZD6474; Drug: Placebo; Drug: ZD1839
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Failure of either first-line and/or second-line chemotherapy either of which was platinum-based (the prior regimen must have failed the subject because of toxicity or progression of tumor * Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV) NSCLC Exclusion Criteria: * Subjects who have received second-line or subsequent chemotherapy * Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SitePine Bluff, Arkansas
- Research SiteLos Angeles, California
- Research SitePalm Springs, California
- Research SiteSan Diego, California
- Research SiteBoca Raton, Florida
- Research SiteJacksonville, Florida
- Research SiteOrange Park, Florida
- Research SiteCoeur d'Alene, Idaho
- Research SiteChicago, Illinois
- Research SiteIndianapolis, Indiana
- Research SiteShreveport, Louisiana
- Research SiteSaint Loius, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 24, 2016. Always confirm current availability with the study team.